Closed Loop Platform Curiverse unifies assay-ready iPSC-derived cells, automated high-throughput systems, and cloud-based data analytics into an end to end platform for industrial-scale, human-relevant drug discovery, offering pharma clients faster, human-relevant decision-making.

Disease Model Leadership The company is expanding disease-model capabilities with hypertrophic cardiomyopathy isogenic pairs and Neuromuscular Junction assays developed with Battelle UK, providing differentiated biological foundations for cardiology and neurology programs.

High Throughput Readouts Nautilai Plus introduces 96-well format contractility force and optical readouts alongside the Stingray maturation engine, enabling high-throughput screening with replicate depth and consistency that appeals to CROs and pharma teams needing scalable functional assays.

Strategic Partnerships Recent partnerships and events, including a Battelle collaboration and Microphysiological Systems World Summit launches, signal a go to market strategy focused on global pharma collaborations and industrial-scale adoption of human-relevant 3D tissue workflows.

AI Analytics Edge An integrated AI ML enabled insights layer and cloud analytics in Curiverse positions Curi Bio to offer data driven decision support, enabling seamless integration with clients pipelines and enhancing assessments of safety, efficacy, and potency.